Paul L. Berns
Paul L. Berns is the co-founder and executive chairman of Neumora and a managing director with ARCH Venture Partners. Mr. Berns has been a member of ARCH Venture Partners since August 2018 and became a Managing Director in 2021. Mr. Berns was a consultant to the biopharmaceutical industry from July 2016 to August 2018, as well as from 2012 to 2014 and from 2005 to 2006. From 2014 to 2016, Mr. Berns served as President Chief Executive Officer and Chairman of the board of directors at Anacor Pharmaceuticals, a biopharmaceutical company, which was acquired by Pfizer in 2016. Previously, Mr. Berns served as President and Chief Executive Officer of Allos Therapeutics, a biopharmaceutical company, from 2006 to 2012, when it was acquired by Spectrum Pharmaceuticals. Mr. Berns was President and Chief Executive Officer of Bone Care International, a specialty pharmaceutical company, from 2002 to 2005, when it was acquired by Genzyme Corporation.
Prior to that, Mr. Berns was Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories from 2001 to 2002, and from 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, when it was acquired by Abbott Laboratories in 2001. Earlier in his career, Mr. Berns held various positions, including senior management roles, at Bristol Myers Squibb (BMS) from 1990 to 2000. Mr. Berns has served as a board member of the publicly held companies UNITY Biotechnology since March 2018 and EQRx since January 2020. Mr. Berns has also served as a board member of the privately held companies Epirium Bio and HI-Bio since July 2019 and August 2021, respectively.
Mr. Berns has served as the chairman of the board of directors of the privately held company Happy AI since July 2019. Mr. Berns previously served on the boards of Jazz Pharmaceuticals, PLC (from 2010 to July 2021), MC2 Therapeutics (from May 2017 to January 2020), Menlo Therapeutics (from November 2017 to March 2020), Anacor Pharmaceuticals (from 2012 to 2016), XenoPort (from 2005 to 2016), Allos Therapeutics (from March 2006 to September 2012) and Bone Care International (from 2002 to 2005). Mr. Berns holds a B.S. in Economics from the University of Wisconsin.